论文部分内容阅读
目的：研制抗人原发性肝癌（ＰＨＣ）特异性单抗（ＭｃＡｂ），为肝癌的导向诊断与治疗奠定基础。方法：用人ＰＨＣ细胞系ＨｅｐＧ２免疫ＢＡＬＢ／ｃ小鼠，取其脾细胞与同源骨髓瘤细胞ＳＰ２／０融合，经间接免疫荧光染色加流式细胞仪筛选及专一性鉴定，单抗经ＰｒｏｔｅｉｎＡ法纯化，用ＳＤＳ聚丙烯酰胺凝胶电泳进行纯度测定。结果：筛选出３株能分泌抗人ＰＨＣ细胞膜单抗的杂交瘤，这些杂交瘤经３次亚克隆后仍能稳定地分泌单克隆抗体。专一性分析显示３株杂交瘤分泌的单抗均可特异性地识别人ＰＨＣ细胞。纯化的单抗属小鼠ＩｇＧｌ亚类。结论：ＭｃＡｂ与肝癌细胞具有较高的亲和力，具有潜在的导向显像和导向治疗的应用价值。
Objective: To develop anti-human primary liver cancer (PHC) monoclonal antibody (McAb), which will lay a foundation for the diagnosis and treatment of liver cancer. METHODS: BALB/c mice were immunized with human PHC cell line HepG2 and the spleen cells were fused with homologous myeloma cells SP2/0. The cells were infiltrated with indirect immunofluorescence staining and flow cytometric analysis and specificity. The purification was performed and the purity was measured by SDS polyacrylamide gel electrophoresis. RESULTS: Three hybridomas capable of secreting anti-human PHC cell membrane monoclonal antibody were screened out. These hybridomas could stably secrete monoclonal antibodies after subcloning three times. Specific analysis showed that the monoclonal antibodies secreted by the three hybridomas could specifically recognize human PHC cells. The purified monoclonal antibodies are mouse IgG1 subclasses. Conclusion: McAb has high affinity with hepatoma cells, and has potential application as guidance imaging and targeted therapy.